UNSPSC 51393103: Guanoxabenz

This classification denotes an alpha-adrenergic agonist with the molecular formula C8H8Cl2N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P9HIK5V7WK, chemically known as 1-((2,6-dichlorobenzylidene)amino)-3-hydroxyguanidine but generally known as guanoxabenz, which bears US NIH Compound Identifier 9567831. European Medicines Agency schedules Guanoxabenz in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14038MIG.

UNSPSC 51393103 Guanoxabenz, a Commodity code, is being solicited by state and local health authorities for pharmaceutical procurement, though recent opportunities show minimal activity directly aligned with the code's nominal scope. The two recent state and local solicitations tagged under this code involve naloxone procurement and direct-to-manufacturer prescription programs — neither of which represents guanoxabenz acquisition. Seminole County, Florida issued an IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford and a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission posted a Request for Information on April 3, 2026, to explore vendor capabilities for implementing a direct-to-manufacturer prescription program for self-insured employee group health plans and state agencies, designed to gather market intelligence before issuing a formal RFP.

Issuing bodies under this code include state health departments and county health authorities. Geographic activity centers on Texas and Florida based on recent postings, though the dataset supports no broader geographic characterization. The Seminole County naloxone IFB carries a due date of July 26, 2023 (appearing in the record with a June 30, 2026 posted date, suggesting a data entry inconsistency), requires electronic bid submission through the county's e-Procurement Portal, mandates drug-free workplace and E-Verify compliance, and features a three-month probationary period with at-will termination rights. The Texas RFI is exploratory rather than a competitive solicitation, seeking vendor experience with direct contracting for self-insured employers and state agencies, negotiated net pricing models without rebates, and outcomes-based or value-based agreements. The code shows limited recent activity genuinely matching guanoxabenz procurement; state and local governments appear to be acquiring naloxone and designing direct-pharmacy programs under this classification rather than pursuing guanoxabenz specifically.